

Updated: 07/2024 Approved: 07/2024

Request for Prior Authorization for Ycanth (cantharidin)
Website Form – www.wv.highmarkhealthoptions.com
Submit request via: Fax - 1-833-547-2030.

All requests for Ycanth (cantharidin) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Ycanth (cantharidin) Prior Authorization Criteria:

Coverage may be provided with a diagnosis of **molluscum contagiosum** and the following criteria is met:

- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines
- The requested dose and frequency are in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Must be prescribed by or in consultation with a dermatologist.
- Documentation of ONE of the following:
 - o Itching, pain, or bleeding associated with lesions
 - o Member is immunocompromised
 - Concomitant bacterial infection
 - o Risk of spread (i.e. sibling, daycare, etc.)
- Documentation of ONE of the following:
 - Member is treating new lesions that have not previously been treated with Ycanth (cantharidin)
 - Lesions have previously been treated with Ycanth (cantharidin) and will not exceed a total of 4 treatments with Ycanth (cantharidin)
- Documentation the member has tried and failed or had an intolerance or contraindication to ONE of the following:
 - Podofilox
 - Cryotherapy
 - o Curettage
 - Laser therapy.
- **Initial Duration of Approval:** 6 months
- Reauthorization criteria
 - o Documentation of ALL of the following:
 - the member has shown improvement from treatment demonstrated by a reduction in the size or number of lesions
 - at least 3 weeks have passed since the previous application
 - total duration of therapy has not exceeded 4 applications
- **Reauthorization Duration of Approval:** 6 months.

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



Updated: 07/2024 Approved: 07/2024

YCANTH (CANTHARIDIN) PRIOR AUTHORIZATION FORM – PAGE 1 OF 2

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. FAX: (833)-547-2030. If needed, you may call to speak to a Pharmacy Services Representative. PHONE: 1-844-325-6251 Mon – Fri 8 am to 7 pm PROVIDER INFORMATION Requesting Provider: NPI: Provider Specialty: Office Contact: Office Address: Office Phone: Office Fax: MEMBER INFORMATION Member Name: DOB: Member ID: Member weight: Height: REQUESTED DRUG INFORMATION Medication: Strength: Refills: Directions: Quantity: Is the member currently receiving requested medication? \(\subseteq \text{Yes} \) No Date Medication Initiated: Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the ☐ Yes ☐ No **Billing Information** This medication will be billed:
at a pharmacy **OR** medically, JCODE: Place of Service: Hospital Provider's office Member's home Other Place of Service Information Name: NPI: Address: Phone: **MEDICAL HISTORY (Complete for ALL requests)** Diagnosis: ICD Code: Is the member experiencing any of the following? (please mark all that apply) Itching, pain, or bleeding associated with lesions Is immunocompromised Has a concomitant bacterial infection There is a risk of spread (i.e. siblings, daycare, etc.) Is the request for new lesions that have not previously been treated?

Yes No Have the lesions previously been treated with Ycanth (cantharidin)? Yes No *If yes how many times and when?* Has the member tried any of the following? (please mark all that apply) podofilox cryotherapy curettage laser therapy **CURRENT or PREVIOUS THERAPY Medication Name** Strength/ Frequency **Dates of Therapy** Status (Discontinued & Why/Current)



Updated: 07/2024 Approved: 07/2024

Т

YCANTH (CANTHARIDIN) PRIOR AUTHORIZATION FORM (CONTINUED) – PAGE 2 OF 2

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation			
as applicable to Highmark Health Options Pharmacy Services. FAX: (833)-547-2030.			
If needed, you may call to speak to a Pharmacy Services Representative. PHONE: 1-844-325-6251 Mon – Fri 8 am to 7 pm			
MEMBER INFORMATION			
Member Name:	DOB:		
Member ID:	Member weigh	ıt:	Height:
REAUTHORIZATION			
Has the member experienced a significant improvement with treatment demonstrated by a reduction in the size or number of lesions? Yes No			
Has at least 3 weeks passed since the previous application? ☐ Yes ☐ No			
How many applications has the member had in the past?			
SUPPORTING INFORMATION or CLINICAL RATIONALE			
Prescribing Provider Signature		D	ate